

KIWA BIO-TECH PRODUCTS GROUP CORP  
Form NT 10-K  
March 30, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

SEC FILE NUMBER: 000-33167  
CUSIP NUMBER: 49834X 10 6

(Check One):  Form 10-K  Form 20-F  Form 11-K  Form 10-Q  Form N-SAR  Form  
N-CSR

For Period Ended: December 31, 2011

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended: \_\_\_\_\_

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I -- REGISTRANT INFORMATION**

Kiwa Bio-Tech Products Group Corporation  
Full Name of Registrant

Former Name if Applicable  
310 N. Indian Hill Boulevard, #702  
Address of Principal Executive Office (*Street and Number*)  
Claremont, CA 91711  
City, State and Zip Code

**PART II – RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

(b) The subject annual report, semi-annual report, transition report on Form 10-Q, Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

### **PART III – NARRATIVE**

State below in reasonable detail the reasons why Forms 10-Q, 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report portion thereof, could not be filed within the prescribed time period.

The Registrant's annual report on Form 10-K could not be filed within the prescribed time period because the financial statements and narrative required could not be completed without unreasonable effort or expense.

The Company expects to file the report within the extension period.

**(Attach Extra Sheets if Needed)**

### **PART IV – OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification

**Wei Li 626 715-5855**  
(Name) (Area Code) (Telephone Number)

(2) Have all  
other  
periodic  
reports  
required  
under  
Section 13  
or 15(d) of  
the  
Securities  
Exchange  
Act of 1934  
or Section  
30 of the  
Investment

Company  
Act of 1940  
during the  
preceding  
12 months  
or for such  
shorter  
period that  
the  
registrant  
was  
required to  
file such  
report(s)  
been filed?  
If answer is  
no, identify  
report(s).

Yes  No

Is it  
anticipated  
that any  
significant  
change in  
results of  
operations  
from the  
corresponding  
(3) period for the  
last fiscal year  
will be  
reflected by  
the earnings  
statements to  
be included in  
the subject  
report or  
portion  
thereof?

Yes  No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Kiwa Bio-Tech Products Group Corporation

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Wei Li

Date: March 30, 2012 By:

Wei Li, Chief Executive Officer and Chairman of the Board of Directors